ReviewNutrition and cancer2016
Cancer chemoprevention research with selenium in the post-SELECT era: Promises and challenges.
Review in Nutrition and cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Selenium for preventing cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Effect of Dietary Methylseleninic Acid and Se-Methylselenocysteine on Carcinogen-Induced, Androgen-Promoted Prostate Carcinogenesis in Rats.Nutrition and cancer · 2022Trial
- A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate.Oncotarget · 2017Trial
- The selenium paradox friend or foe in breast cancer?Annals of medicine and surgery (2012) · 2025Review
- Activation of the De Novo Serine Synthesis Pathway and Disruption of Insulin Signaling Induced by Supplemental SeMet in Vitro.Biological trace element research · 2025Article
- Selenium compounds for cancer prevention and therapy - human clinical trial considerations.Medical review (2021) · 2025Review
- Review
- A comprehensive review on potential role of selenium, selenoproteins and selenium nanoparticles in male fertility.Heliyon · 2024Review
- Combination of Selenite and Butyrate Enhances Efficacy Against Colon Cancer by Targeting ASCT2-Mediated Amino Acid Metabolism.Biological trace element research · 2024Article
- Fractionation of selenium isotopes during biofortification of Saccharomyces cerevisiae and the influence of metabolic labeling withJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2023Article
- Research Progress of Selenium-Enriched Foods.Nutrients · 2023Review
- First Generation of Antioxidant Precursors for Bioisosteric Se-NSAIDs: Design, Synthesis, and In Vitro and In Vivo Anticancer Evaluation.Antioxidants (Basel, Switzerland) · 2023Article
- Metabolism and Anticancer Mechanisms of Selocompounds: Comprehensive Review.Biological trace element research · 2023Review
- Selenium Yeast and Fish Oil Combination Diminishes Cancer Stem Cell Traits and Reverses Cisplatin Resistance in A549 Sphere Cells.Nutrients · 2022Article
- Metallomic and Untargeted Metabolomic Signatures of Human Milk from SARS-CoV-2 Positive Mothers.Molecular nutrition & food research · 2022Observational
- Selenium supplementation influences mice testicular selenoproteins driven by gut microbiota.Scientific reports · 2022Article
- Untargeted Gut Metabolomics to Delve the Interplay between Selenium Supplementation and Gut Microbiota.Journal of proteome research · 2022Article
- Sodium Selenite Regulates the Proliferation and Apoptosis of Gastric Cancer Cells by Suppressing the Expression of LncRNA HOXB-AS1.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Evaluating agreement between bodies of evidence from randomised controlled trials and cohort studies in nutrition research: meta-epidemiological study.BMJ (Clinical research ed.) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
The negative efficacy outcomes of double-blinded, randomized, placebo-controlled Phase III human clinical trials with selenomethionine (SeMet) and SeMet-rich selenized-yeast (Se-yeast) for prostate cancer prevention and Se-yeast for prevention of nonsmall cell lung cancer (NSCLC) in North America lead to rejection of SeMet/Se-yeast for cancer prevention in Se-adequate populations. We identify 2 major lessons from the outcomes of these trials: 1) the antioxidant hypothesis was tested in wrong subjects or patient populations, and 2) the selection of Se agents was not supported by cell culture and preclinical animal efficacy data as is common in drug development. We propose that next-generation forms of Se (next-gen Se), such as methylselenol precursors, offer biologically appropriate approaches for cancer chemoprevention but these are faced with formidable challenges. Solid mechanism-based preclinical efficacy assessments and comprehensive safety studies with next-gen Se will be essential to revitalize the idea of cancer chemoprevention with Se in the post-SELECT era. We advocate smaller mechanism-driven Phase I/II trials with these next-gen Se to guide and justify future decisions for definitive Phase III chemoprevention efficacy trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.